R15 AREA: Optimizing allosteric modulation of noncoding regulatory RNA function
R15 AREA: Optimizing allosteric modulation of noncoding regulatory RNA function
批准号:
10730685
负责人:
JENNIFER V HINES
金额:
$45.3万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-05-01 至 2026-08-31
关键词:
AchievementAnti-Bacterial AgentsAntibioticsBacteriaBacterial Drug ResistanceBacterial InfectionsBindingBiological AssayBiomedical ResearchCell physiologyChemicalsCommunicable DiseasesComputing MethodologiesConserved SequenceDevelopmentDockingDrug TargetingElementsEligibility DeterminationEssential GenesFutureGram-Positive BacteriaGrantHealthHumanIn VitroInfectionKnowledgeLeadLigand BindingLigandsLocationMalignant NeoplasmsMedicineMethodsMinimum Inhibitory Concentration measurementModerate ActivityNational Institute of General Medical SciencesOutcomeOxazolidinonesPathogenicityProcessPublic HealthRNARNA BindingResistanceScientistScoring MethodSpecificityTestingTherapeutic AgentsTrainingUntranslated RNAViralWaterWorkantagonistanti-cancercareercomputer studiesdesigndrug discoveryexperienceglobal healthhigh throughput screeningimprovedinhibitorinnovationmolecular dynamicsnext generationnovelnovel therapeuticsrational designsmall moleculesuccessundergraduate researchundergraduate student
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Bacterial drug resistance is a significant global health threat that has turned once treatable
bacterial infections (including Gram-positive infections) into deadly illnesses. To overcome this
serious threat to human health, completely novel antibiotics are needed. The T-box riboswitch is
a noncoding RNA that regulates the expression of essential genes in many Gram-positive
bacteria (including pathogenic examples), thus making it a unique target for novel antibacterial
agents. A key component of the T-box riboswitch regulatory mechanism involves tRNA binding
to the highly conserved antiterminator RNA element--an excellent target for drug discovery. This
project will explore the rational design of allosteric modulators of T-box antiterminator RNA
function and compare their efficacy to that of competitive inhibitors. No therapeutic agents are
currently known to specifically target the T-box riboswitch.
Our prior studies indicate that riboswitch inhibition can occur through negative allosteric
modulation of the antiterminator rather than direct competition with the riboswitch’s cognate
ligand (tRNA). Consequently, this proposal seeks to identify compounds with improved activity
based on the following hypothesis: Leveraging allosteric modulation is an effective drug
discovery strategy for targeting noncoding RNA function. Specifically, we plan to use
computational methods to design the next generation of compounds that inhibit T-box riboswitch
function. An optimized high throughput screening protocol will be developed that includes
induced-fit docking and refined scoring methods. We will synthesize sets of 3 different
compounds that have either shown activity in preliminary RNA studies or have been designed
through initial computational studies. Select compounds will be characterized to quantify
riboswitch inhibitory concentration (IC50), antiterminator binding (selectivity, Kd), RNA binding
mode, and minimum inhibitory concentrations.
Achievement of the proposed specific aims will improve scientific knowledge by developing
design strategies to identify inhibitors (including allosteric modulators) of RNA function and by
exploring the most effective chemical space features of these small molecules. This information
will be significant for antibacterial drug discovery targeting the T-box riboswitch and also for the
still emerging broader field of targeting noncoding regulatory RNA in general for antibacterial,
antiviral, anticancer and other drug discovery efforts. In the process, a team of primarily
undergraduate students will gain first-hand experience working on an innovative drug discovery
project that will inspire them to consider careers in biomedical research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting a novel regulatory RNA with novel antibiotics
-
批准号:8002972
-
项目类别:
-
资助金额:$4.94万
-
财政年份:2010
-
负责人:JENNIFER V HINES
-
依托单位:
Targeting a novel regulatory RNA with novel antibiotics
-
批准号:7574476
-
项目类别:
-
资助金额:$46.12万
-
财政年份:2007
-
负责人:JENNIFER V HINES
-
依托单位:
Targeting a novel regulatory RNA with novel antibiotics
-
批准号:7760100
-
项目类别:
-
资助金额:$46.87万
-
财政年份:2007
-
负责人:JENNIFER V HINES
-
依托单位:
Targeting a novel regulatory RNA with novel antibiotics
-
批准号:7340737
-
项目类别:
-
资助金额:$46.4万
-
财政年份:2007
-
负责人:JENNIFER V HINES
-
依托单位:
Targeting a novel regulatory RNA with novel antibiotics
-
批准号:7197553
-
项目类别:
-
资助金额:$47.43万
-
财政年份:2007
-
负责人:JENNIFER V HINES
-
依托单位:
Targeting a novel regulatory RNA with novel antibiotics
-
批准号:7477397
-
项目类别:
-
资助金额:$1.08万
-
财政年份:2007
-
负责人:JENNIFER V HINES
-
依托单位:
Structure Function Studies of a RNA Antiterminator Bulge
-
批准号:6619729
-
项目类别:
-
资助金额:$22.84万
-
财政年份:2001
-
负责人:JENNIFER V HINES
-
依托单位:
Structure Function Studies of a RNA Antiterminator Bulge
-
批准号:6399571
-
项目类别:
-
资助金额:$22.55万
-
财政年份:2001
-
负责人:JENNIFER V HINES
-
依托单位:
Structure Function Studies of a RNA Antiterminator Bulge
-
批准号:6784021
-
项目类别:
-
资助金额:$22.84万
-
财政年份:2001
-
负责人:JENNIFER V HINES
-
依托单位:
Structure Function Studies of a RNA Antiterminator Bulge
-
批准号:6526210
-
项目类别:
-
资助金额:$22.84万
-
财政年份:2001
-
负责人:JENNIFER V HINES
-
依托单位:
Structure Function Studies of a RNA Antiterminator Bulge
-
批准号:6930337
-
项目类别:
-
资助金额:$22.84万
-
财政年份:2001
-
负责人:JENNIFER V HINES
-
依托单位:
海外基金